Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
June 24, 2024 12:28 PM EDT
Morgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $250.00 (from $164.00) while maintaining a Equalweight rating.
The analyst comments "Top-line HELIOS-B results better-than-expected, supporting sNDA filing in late 2024. We expect focus to now shift to presentation of... More
June 24, 2024 11:38 AM EDT
RBC Capital analyst Luca Issi reiterated an Outperform rating and $235.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "The News: Highly anticipated HELIOS-B hits the primary endpoint (composite of all-cause mortality and recurrent CV events) in both ITT (HR 0.718, p-value 0.0118; n=654) and monotherapy (HR... More
June 24, 2024 7:28 AM EDT
Stifel analyst Paul Matteis reiterated a Buy rating and $247.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "We believe topline HELIOS-B data are highly positive and support vutrisiran becoming a blockbuster in TTR-cardiomyopathy. Specifically the trial met all... More
June 24, 2024 7:11 AM EDT
Alnylam Pharma (NASDAQ: ALNY) to Resume Trading at 7:30 a.m.
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population Achieved 28% and 33% Reduction in Composite...
More
